O-desmethyltramadol

Drug Profile

O-desmethyltramadol

Alternative Names: O-DSMT; Omnitram

Latest Information Update: 29 Apr 2016

Price : $50

At a glance

  • Originator Syntrix Biosystems
  • Class Cyclohexanols; Dimethylamines; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 29 Apr 2016 Phase-I development is ongoing in USA
  • 01 Oct 2014 Syntrix completes a phase I trial in Pain (In volunteers) in Japan (NCT02205554)
  • 01 Aug 2014 Phase-I clinical trials in Pain (In volunteers) in USA (PO) (NCT02205554)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top